Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection

Curr Opin Investig Drugs. 2008 Aug;9(8):899-912.

Abstract

Tibotec BVBA is developing the diarylpyrimidine rilpivirine, a second-generation non-nucleoside reverse transcriptase inhibitor for the potential treatment of HIV infection. A phase III trial of rilpivirine in HIV-infected, treatment-naive indivuduals is underway and is to be completed by August 2010.

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials as Topic
  • Drug Evaluation, Preclinical
  • Drug Interactions
  • HIV Infections / drug therapy*
  • HIV Reverse Transcriptase / antagonists & inhibitors
  • Humans
  • Nitriles / administration & dosage*
  • Nitriles / adverse effects
  • Nitriles / pharmacokinetics
  • Patents as Topic
  • Pyrimidines / administration & dosage*
  • Pyrimidines / adverse effects
  • Pyrimidines / pharmacokinetics
  • Reverse Transcriptase Inhibitors / administration & dosage*
  • Reverse Transcriptase Inhibitors / adverse effects
  • Reverse Transcriptase Inhibitors / pharmacokinetics
  • Rilpivirine

Substances

  • Nitriles
  • Pyrimidines
  • Reverse Transcriptase Inhibitors
  • HIV Reverse Transcriptase
  • Rilpivirine